{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.2","upperLimit":"1.4","value":"-0.4"},{"groupId":"OG001","lowerLimit":"-1.4","upperLimit":"2.2","value":"0.4"}]}],"title":"Change from baseline EORTC QLQ-C30 Global health status score to 6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-1.5","upperLimit":"2.4","value":"0.5"},{"groupId":"OG001","lowerLimit":"0.7","upperLimit":"4.7","value":"2.7"}]}],"title":"Change from baseline EORTC QLQ-C30 Global health status score to 12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.3","upperLimit":"5.3","value":"3.3"},{"groupId":"OG001","lowerLimit":"2.3","upperLimit":"6.4","value":"4.4"}]}],"title":"Change from baseline EORTC QLQ-C30 Global health status score to 18 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"5.0","value":"2.8"},{"groupId":"OG001","lowerLimit":"3.8","upperLimit":"8.4","value":"6.1"}]}],"title":"Change from baseline EORTC QLQ-C30 Global health status score to 24 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"382"},{"groupId":"OG001","value":"358"}],"units":"Participants"}],"description":"Change from baseline for EORTC QLQ-C30 Global health status QOL (Quality of Life) Score at 6, 12, 18 and 24 months for patients who completed neoadjuvant chemotherapy. Adjusted least-square mean changes and 95% CI are obtained from mixed model for repeated measures (MMRM) analysis of the change from baseline. Only patients with evaluable baseline forms are included. EORTC QLQ-C30 scores range from 0 to 100 with higher score indicating better quality of life.","dispersionType":"95% Confidence Interval","groups":[{"description":"Olaparib tablets 300mg taken orally twice daily.","id":"OG000","title":"Olaparib"},{"description":"Placebo tablets taken orally twice daily.","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"Patient reported outcomes (PRO) Analysis Set","reportingStatus":"POSTED","timeFrame":"6, 12, 18 and 24 months after randomisation (data cut off: 12 July 2021)","title":"Change From Baseline for EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core Questions 30) Scores for Participants Who Completed Neoadjuvant Chemotherapy","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}